Home » Topics » Disease categories and therapies » Ocular

Ocular
RSS

Retisert launched for chronic noninfectious uveitis

July 6, 2005

No Comments

First phase III study begins for Evizon in wet AMD

July 5, 2005

No Comments

Oxigene updates vascular targeting programs in ophthalmology

July 1, 2005

No Comments

Genaera reaches SPA agreement on phase III trials for Evizon

June 30, 2005

No Comments

Pre-NDA meeting for AzaSite

June 30, 2005

No Comments

Sucampo suspends tacrolimus eye drops development program

June 29, 2005

No Comments

Duska acquires P2 receptor-based technology to treat glaucoma

June 21, 2005

No Comments

Enzo acquires rights to drug candidate for treating uveitis

June 16, 2005

No Comments

Potassium channel blockers for glaucoma, etc., emerge from Merck & Co. research

June 14, 2005

No Comments

Target enrollment reached in phase II wet AMD study of Evizon

June 13, 2005

No Comments

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Ocular
RSS

Retisert launched for chronic noninfectious uveitis

First phase III study begins for Evizon in wet AMD

Oxigene updates vascular targeting programs in ophthalmology

Genaera reaches SPA agreement on phase III trials for Evizon

Pre-NDA meeting for AzaSite

Sucampo suspends tacrolimus eye drops development program

Duska acquires P2 receptor-based technology to treat glaucoma

Enzo acquires rights to drug candidate for treating uveitis

Potassium channel blockers for glaucoma, etc., emerge from Merck & Co. research

Target enrollment reached in phase II wet AMD study of Evizon

Today's news in brief

Today's news in brief

Caplyta star shines as J&J takes Intra-Cellular in $14.6B deal

Proteomics study explores how protein changes influence disease

Abbvie and Simcere enter a $1B T-cell engager deal

Ocular RSS

Ocular
RSS